Sign in Subscribe
Nuclear energy

Canadian Nuclear Laboratories and University of Ottawa Partner to Advance Low-Dose Radiation Research

Strategic Insights

— 2 min read

Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, and the University of Ottawa (uOttawa) are collaborating to advance knowledge, education, research, and innovation in low dose radiation (LDR) exposure health effects. This partnership leverages the leading research organizations' complementary capabilities, building on CNL's global leadership in LDR research. The new partnership aims to increase capabilities, education, and training opportunities for graduate students and early-career researchers. The collaboration will also extend uOttawa researchers' access to Atomic Energy of Canada Limited's world-class facilities at Chalk River Laboratories.

Key Takeaways:

  • The partnership will focus on advancing knowledge, education, research, and innovation in low dose radiation (LDR) exposure health effects, leveraging CNL's global leadership in LDR research.
  • The collaboration will increase capabilities, education, and training opportunities for graduate students and early-career researchers.
  • uOttawa researchers will gain access to Atomic Energy of Canada Limited's world-class facilities at Chalk River Laboratories, including the unique Biological Research Facility and associated irradiation facilities.
  • A CNL satellite laboratory will be established within uOttawa's new Advanced Medical Research Centre (AMRC), co-located with the Ottawa Institute of Systems Biology and uOttawa's state-of-the-art Core Facilities.
  • The partnership will support new research directions in radiation sciences and advanced organoid-based systems biology, positioning the university as a national and potentially international leader in this field.
  • CNL will contribute towards the acquisition of a mass spectrometer, which will be installed in the Metabolomics Core Facility at uOttawa, enabling leading-edge single-cell metabolomics and spatial metabolomics research.
  • The mass spectrometer will be a central component of the new Spatial Biology and Single-Cell Suite (3S) within the AMRC, integrating transformative new technologies into a coordinated workflow.
  • The partnership builds on over a decade of collaborative research involving CNL and multiple uOttawa faculties, advancing understanding of the biomedical impacts of LDR.

Statistics:

  • 10 years of collaborative research between CNL and uOttawa faculties, including Engineering, Science, and Medicine, have advanced understanding of the biomedical impacts of LDR.
  • CNL has provided funding support for postdoctoral fellow stipends, further enabling high-impact research and talent development.
  • The partnership will establish a CNL satellite laboratory within uOttawa's new AMRC, co-located with the Ottawa Institute of Systems Biology and uOttawa's state-of-the-art Core Facilities.
  • The mass spectrometer will be the only equipment of its kind in eastern Canada, offering unique capabilities for high-resolution chemical imaging at the cellular level.

Sources:

  • Canadian Nuclear Laboratories (CNL)
  • University of Ottawa (uOttawa)
  • Atomic Energy of Canada Limited (AECL)
  • GlobeNewswire (MIL-OSI)
  • https://www.globenewswire.com/NewsRoom/AttachmentNg/8c4cd1c0-401a-44e6-83ce-e65ea78dc6b4

Read more